— Know what they know.
Not Investment Advice

PKI

PerkinElmer, Inc.
1W: +5.3% 1M: -10.8% 3M: -6.6% 1Y: -17.8% 3Y: +30.8% 5Y: +59.5%
$115.24
Last traded 2023-05-23 — delisted
NYSE · Healthcare · Medical - Diagnostics & Research · $14.5B
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$14.5B
52W Range113.17-170.0
Volume1,633,024
Avg Volume811,897
Beta1.10
Dividend$0.28
Analyst Ratings
13 Buy 18 Hold 0 Sell
Consensus Hold
Company Info
CEOPrahlad R. Singh
Employees16,700
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date1983-04-06
940 Winter Street
Waltham, MA 02451
US
781 663 6900
About PerkinElmer, Inc.

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Gonzales Anita A-Award 248 2023-12-15
Gonzales Anita A-Award 706 $101.36 2023-12-15
MICHAS ALEXIS P G-Gift 230 2023-11-28
MICHAS ALEXIS P G-Gift 250 2023-11-27
Gonzales Anita A-Award 329 2023-06-15

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms